Abzena was established in 2013 when two companies, PolyTherics and Antitope, were combined to create a single leading provider of technologies and services to enable better biopharmaceuticals.
Located in the UK, PolyTherics was founded in 2001, and was viewed as an innovator in the bioconjugate space. The company specialized in proprietary site-specific conjugation technologies for antibody drug conjugate development and solutions for optimization of the therapeutic properties of biopharmaceuticals. They were the creators of Abzena's unique ThioBridge platform, which has been proven to enhance the development of antibody drug conjugates (ADCs) by overcoming challenges and improving stability, potency and efficacy.
Also located in the UK, Antitope, founded in 2004, was considered to be an industry leader in immunogenicity assessment, protein engineering to create humanized antibodies and deimmunized therapeutic proteins and cell line development for manufacture. They were the creators of EpiScreen, a robust ex-vivo immunogenicity assessment platform and Composite Human Antibody and Composite Protein platforms, which reduce immunogenicity risk and confidently move antibodies and complex biologics forward into development.
Together they served a global customer base including the top multinational large pharmaceutical groups to emerging biotechs.